SecBot SecBot
8-K ·Filed Jul 23, 2026

DGX

QUEST DIAGNOSTICS INC
BULLISH
Impact 7/10
Horizonimmediate Processed3mo ago SEC0001022079-26-000067
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The strong beat and second consecutive guidance raise confirm robust demand across physician, hospital, and consumer channels. Traders should expect a positive reaction, but monitor the 2.8% decline in revenue per requisition and slight margin compression as potential headwinds. The raised cash flow guidance to ~$1.80B supports continued capital returns.

DirectionBullish
Confidencehigh
Horizonimmediate

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$227.90
T+0 close · Jul 23, 2026 · via day close
Latest settled
+4.94%
T+60 · $239.15
Vs SPY
+0.38%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 23 $227.90entry
  2. T+1 · 4mo ago −0.02%α −0.12% · $227.86
  3. T+5 · 4mo ago +2.81%α +2.33% · $234.30
  4. T+20 · 3mo ago +5.88%α +2.57% · $241.30
  5. T+60 · 4w ago +4.94%α +0.38% · $239.15
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Quest Diagnostics reported Q2 2026 adjusted EPS of $3.12, beating consensus of $2.82 by 10.6%, and revenue of $3.04B, beating $2.97B by 2.5%. The company raised full-year 2026 guidance for the second consecutive quarter, now expecting revenue of $11.95B-$12.05B and adjusted EPS of $11.05-$11.25, driven by 10.2% revenue growth and 19.1% adjusted EPS growth.

Key Financial Metrics

EPS
$3.12
est $2.82 · +10.6%
Revenue
$3.0B
est $3.0B · +2.5% · +10.2% YoY
Rating
strong beat
Guidance
$11.95B-$12.05B
raised

Key Facts

  • Q2 2026 revenue $3.04B, up 10.2% YoY (10.0% organic)
  • Adjusted diluted EPS $3.12, up 19.1% YoY, beat consensus by 10.6%
  • Full-year 2026 revenue guidance raised to $11.95B-$12.05B (prior $11.78B-$11.90B)
  • Full-year 2026 adjusted EPS guidance raised to $11.05-$11.25 (prior $10.63-$10.83)
  • Operating cash flow $597M in Q2, up 9.7% YoY; capex $138M
  • Requisition volume grew 13.1% (organic 13.0%), but revenue per requisition declined 2.8%

Financial Impact

Revenue beat by ~$73M; EPS beat by $0.30; guidance raised by ~$170M at midpoint for revenue and $0.42 for adjusted EPS

revenueepsguidanceoperating cash flow

Risk Factors

  • Revenue per requisition declined 2.8% YoY, indicating mix shift or pricing pressure
  • Reported operating margin contracted to 15.1% from 15.9% (adjusted 16.5% vs 16.9%)

Market Snapshot

Exchange
NYSE
Sector
Services-Medical Laboratories
Analyst Consensus
57% bullish (23 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001022079-26-000067
Document: dgx-20260723.htm0001022079-26-000067
Document: 0001022079-26-000067-index-headers.html0001022079-26-000067
Document: 0001022079-26-000067-index.html0001022079-26-000067
Document: 0001022079-26-000067.txt0001022079-26-000067
8-K Data (Synthetic)0001022079-26-000067

US Market Status

Market Open · Closes in 10m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 23, 2026